STOCK TITAN

Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022.

The conference call will be held on July 14, 2022 at 8:30 a.m. (ET) to discuss the results and recent business updates. The call will be hosted by Paul Lévesque, President and Chief Executive Officer. Joining Mr. Lévesque on the call will be other members of the management team, including Chief Financial Officer Philippe Dubuc and Chief Medical Officer Christian Marsolais, who will be available to answer questions from participants following prepared remarks.  

Participants are encouraged to join the call ten minutes in advance to secure access.

Conference call dial-in and replay information is below:

CONFERENCE CALL INFORMATION
Conference Call Date:July 14, 2022
Conference Call Time:8:30 AM ET
North America Dial-in:1- 877-513-4119
International Dial-in:1- 412-902-6615
Access Code:5742327
CONFERENCE CALL REPLAY
North America Dial-in:1- 877-344-7529
International Dial-in:1- 412-317-0088
Replay Access Code: 7192794
Replay End DateJuly 21, 2022

The live conference call will be accessible via webcast at: https://edge.media-server.com/mmc/p/98pvag4g.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

Investors:
Elif McDonald
Senior Director, Investor Relations
1-438-315-8563   
ir@theratech.com 


Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

58.85M
34.20M
6.29%
50.89%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Montreal

About THTX

theratechnologies inc., a biopharmaceutical company, markets prescription products in the united states, europe, and canada. it offers egrifta and egrifta sv, for the reduction of excess abdominal fat in human immunodeficiency virus (hiv)-infected patients with lipodystrophy; and trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant hiv-1 infected patients. the company's pipeline products include f8 formulation that could be used for the treatment of hiv-associated lipodystrophy; th-1902 for the treatment of triple negative breast cancer; and th-1904 for the treatment of ovarian cancer. the company was founded in 1993 and is headquartered in montreal, canada.